2018
DOI: 10.1016/j.jval.2018.04.250
|View full text |Cite
|
Sign up to set email alerts
|

How Will Payers Manage The High Cost Of Combinations Of New Oncology Agents, As Many Of These Therapies Become The Preferred Treatment Options To Optimize Patient Outcomes?

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles